Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDCT in lumbar degenerative disc disease
NCT03955315Phase 1Completed
- Sponsor
- DiscGenics
- Start
- May 2019
- Primary completion
- Feb 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rebonuputemcel in degenerative disc disease (DDD) (3 arms), sponsored by DiscGenics. Primary endpoints: Adverse Events at 1 year and Visual Analogue Scale at 6 months. Started May 2019; status: completed.
02
Drugs
rebonuputemcel
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03955315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955315.